CLAIMS

1. A combination comprising :

a compound A, which is (2*R*)-2-(4-fluorophenyl)-*N*-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-*a*]pyridin-6-yl)phenyl]propanamide

or a hydrate, a solvate, or a salt thereof, or a mixture of same;

and

a mitotic inhibitor, which is vincristine, docetaxel or paclitaxel.

2. The combination according to claim 1, further comprising cisplatin.

3. The combination according to claim 1 or 2 for use in the treatment or prophylaxis of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.

4. Use of a combination according to claim 1 or 2 in the manufacture of a medicament for the treatment or prophylaxis of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.

5. A kit comprising a combination of :

component A : which is compound A, as defined in claim 1;

and

component B : a mitotic inhibitor, selected from docetaxel, paclitaxel, and vincristine;

and, optionally, one or more further pharmaceutical agents C; in which optionally all or either of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

6. The kit according to claim 5, wherein the mitotic inhibitor is selected from docetaxel, paclitaxel and the optional pharmaceutical agent C is cisplatin.